ABVX:EPA
Abivax SA
77,70 €
arrow_upward
+0,71%(+0,55) 1D
9-ноя., 17:39:42 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
77,95 €
High
79,40 €
Low
76,65 €
Mkt. cap
6,86 млд
Avg. vol.
112,93 миң
Volume
119,78 миң
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
Open
77,95 €
High
79,40 €
Low
76,65 €
Mkt. cap
6,86 млд
Avg. vol.
112,93 миң
Volume
119,78 миң
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
News stories
From web sources and news partners
Idéal Investisseur
·
11 саат мурун
Abivax shares drop 31% over three months and remain below their averages
Yahoo! Finance Canada
·
2 күн мурун
ABIVAX Société Anonyme (ABVX) Seasonal Returns Chart - Yahoo Finance
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded2013-ж., 4-дек.
Headquarters-
SectorHealth Care
Industry-
Websiteabivax.com